Day Two

March 1 2012

8.00 Registration, Coffee & Networking

8.50 Chair’s Opening Remarks

Alain Beck, Director, Physico-Chemistry Department, Centre d’Immunologie Pierre Fabre

9.00 ADC Competitive Landscape: An Industry Perspective

• Old and new players in the field
• Map of ADCs currently in clinical development
• New areas of investigation

Grazia Piizi, Chemistry Project Leader, Novartis

Dispatches From The Clinic

9.30 Antibody-Drug Conjugates: An Emerging Modality for the Targeted Therapy of Liquid and Solid Tumours

• Update on preclinical and clinical programs at Pfizer
• Clinical update on CMC-544, an anti-CD22 calicheamicin conjugate
• Preclinical data on an ADC targeting a tumour associated antigen, 5T4, expressed on tumour initiating cells in models of NSCLC

Puja Sapra, Director, Pfizer

10.00 Update on PSMA ADC, a Clinical-Stage Antibody-Drug Conjugate

• PSMA ADC is a vcMMAE-based ADC that targets prostate-specific membrane antigen (PSMA)
• Hear the latest clinical results in prostate cancer
• Learn of potential applications for anti-neovascular targeting of other cancers

William Olson, Senior Vice President, R&D, Progenics

10.30 Morning Refreshments

11.00 BT-062: An Antibody Drug Conjugate for the Treatment of CD138 Expressing Tumours

• Approaches for conjugate optimisation and preclinical development
• Data from clinical trials in multiple myeloma provide evidence of clinical efficacy and good tolerability
• BT-062 induces complete remission of human solid tumours in mouse models

Christoph Uherek, Head of Preclinical Development, Biotherapeutics, Biotest

11.30 Phase I Clinical Program for the Novel ADC AGS-16M8F

• Target selection: AGS-16 hits a single transmembrane antigen that is up-regulated in the majority of renal cancers
• An insight into the sequencing of AGS-16
• Developing AGS-16M8F - a unique antibody drug conjugate with significant preclinical activity in metastatic renal cell carcinoma

Leonard Reyno, Senior Vice President & CMO, Agensys

Preclinical Innovations To Fuel The Development Of The ADCs Of Tomorrow

12.00 Digoxigenin-Binding Bispecific Antibodies for Targeted Payload Delivery

• Stable bispecific antibodies that bind haptens as well as cell surface antigens
• Defined complexes of bispecific antibodies and digoxygeninylated payloads
• Antibody-mediated targeted payload delivery

Ulrich Brinkmann, Scientific Director, Roche

12.30 Lunch

13.30 Preclinical Development of a Novel ADC for Breast Cancer

• Examining the effector function of naked Ab alone
• Lessons learned from conducting the in vitro analysis of ADC
• An overview of the rodent and primate PK/PD studies
• Demonstrating potent activity in in vivo xenograft models

Andy Simmons, Senior Scientist, Takeda San Francisco

14.00 Development of Drug-Conjugated Monoclonal Antibodies Against Tissue Factor for Treatment of Solid Tumours

• Evaluating tissue factor’s physiological function, MOA and its role as a novel ADC target
• Development and characterisation of antibodies against TF
• Exploring HuMax-TF-ADC’s potential for tumour reduction utilising A431 and HPAF-II xenograft models

David Satijn, Associate Director, Genmab

14.30 Afternoon Refreshments

15.00 Discovery & Preclinical Evaluation of New Maytansinoid ADC Product Candidates

• Rationale for ADC target selection
• Considerations for the discovery and selection of optimal antibodies
• Strategies for preclinical assessment of maytansinoid ADCs

Tom Chittenden, Executive Director, Research, ImmunoGen

15.30 Light-Activated Antibody Fragment-Drug Conjugates

• Developing single-chain Fv frameworks that are optimised for accommodating targeted photodynamic therapy (PDT) drugs
• Assessing the pharmacokinetics of antibody fragments versus classical antibodies and their suitability conjugation with PDT drugs
• Preclinical results from challenging animal models for ovarian and prostate cancer with scFv-based ADCs activated by laser light

Mahendra Deonarain, Reader in Antibody Technology, Imperial College London

16.00 Chair’s Closing Remarks